Status:
COMPLETED
HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to ca...
Detailed Description
OBJECTIVES: * Correlate clinical response to trastuzumab (Herceptin®) with the presence of mutation in the HER-2 kinase domain in tumor samples from patients with advanced non-small cell lung cancer ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of non-small cell lung cancer meeting ≥ 1 of the following criteria:
- Recurrent disease
- Stage IIIB with pleural or pericardial effusion
- Stage IV disease
- Treated on protocol ECOG-2598
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
February 2 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 2 2006
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00896909
Start Date
February 2 2006
End Date
July 2 2006
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.